DEVELOPING TOMORROW’S CANCER THERAPIES. TODAY.

Corporate profile

  • Private – spin-out from APEIRON Biologics AG
  • Launched in January 2022
  • Highly experienced management team with strong scientific and capital markets expertise
  • In-house acumen in discovery, development, clinical trials, CMC and finance
  • Seeking funding through equity investment and or partnering

Investment case: Excellent basis for future value growth

  • Unencumbered focus on discovery and development of innovative cancer immunotherapies
  • Proprietary cell-therapy platform enabling out-patient treatment of hard-to-access solid tumors
    • Individualised, patient-centric approach
    • Shown to be safe and well-tolerated in clinical trials
    • Lead candidate expected to enter Phase 2 in 2024
  • Complementary, high-potential orally available small molecule for tumor-specific immune activation and tumor-cell killing
  • In-house innovation hub driving long-term pipeline growth

Innovative immuno-oncology pipeline

TARGETSPROJECTSEARLY STAGECLINICAL
DISCOVERYPRECLINICALPHASE 1PHASE 2PHASE 3
Cbl-b

(via platform)
APN401
· Various solid tumors
· PBMCs using siRNA
INV441
· Glioblastoma
· TILs using siRNA
Immune activationINV501
· Melanoma & glioblastoma
· Small molecule for oral           application

Why we target Cbl-b

  • Modulating Cbl-b is central to fighting tumor cells in a broad range of tumor indications
  • Cbl-b is involved in several negative regulatory pathways
  • Cbl-b deficiency activates a variety of immune cells for tumor destruction

For further information, please visit our main website:

Innovative immuno-oncology pipeline

TargetsProjectsEARLY STAGECLINICAL
DISCOVERYPRECLINICALPHASE 1PHASE 2PHASE 3
Cbl-b

(via EPIC platform)
APN401

· Various solid tumors
· PBMCs using siRNA
INV441

· Glioblastoma
· TILs using siRNA
Immune activationINV501
· Various solid tumors
· Small molecule for oral           application

Why we target Cbl-b

  • Modulating Cbl-b is central to fighting tumor cells in a broad range of tumor indications
  • Cbl-b is involved in several negative regulatory pathways
  • Cbl-b deficiency activates a variety of immune cells for tumor destruction

For further information, please visit our main website: